Granules India Ltd
GRANULES (NSE)

325.20

8,144.51
Proj. ROE (%)
20.81
Proj. P/E (x)
14.68
Proj EV / EBITDA (x)
9.44
Proj. P/BV (x)
2.99
Proj. Revenue ( Cr.)
3,732.27

Stock View

BUY
Share on
The average score for Granules India Ltd stands at 5 against 8, three months back.

Granules India Limited is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The Company's business operations include three areas: core business, emerging business, and contract research and manufacturing services (CRAMS). Its products in Core business include Paracetamol, Ibuprofen, Guaifenesin and Metformin. The Company operates a healthcare division, Granules Consumer Healthcare (GCH). The Company, through an acquisition, has access to over 10 APIs, as well as intermediates in therapeutic categories, such as anti-histaminic, antihypertensive and anti-convulsants. The Company's PFI products include Compresso PAP 97 S, Compresso PAP 90 CPC and Paracetamol Caffeine Combo 77.4. The Company's FDs include Paracetamol/Acetaminophen, and Acetaminophen and Methocarbamol.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
337.15
100 DMA ()
339.35
200 DMA ()
338.59
52 Weeks Range
295.00
437.95
Street View :-
Bearish
Open ZERO Brokerage Demat Account